A proven target class. An untapped modality.

GPCRs are the most successful drug target family in medicine: roughly a third of approved drugs act on them. Yet only a handful of approved antibodies target GPCRs, because these receptors are small, flexible and embedded in the cell membrane. Antibodies can bring what small molecules often cannot – selectivity between related receptors, long dosing intervals and bispecific formats. 

Computation-first. Experimentally validated.

Our proprietary RedQueenTM engine evolves antibodies in silico against the structure of each receptor, combining evolutionary computation, physics-based modeling and AI. Every candidate is then produced and tested in the lab – binding, expression and pharmacology – before it enters our pipeline. The aim: more high-quality hits on goal per euro, against targets conventional discovery struggles with.